Forget Novo Nordisk: Buy This Magnificent Pharma Stock Instead
Novo Nordisk (NYSE: NVO) is enjoying one of the best seasons in its history. Two of the company's drugs, Ozempic and Wegovy, have become household names. Novo's sales and profits are soaring. So is its share price, with the stock up around 150% over the last three years.
Some investors who didn't buy Novo Nordisk earlier could be considering jumping on the bandwagon now. I have an alternate idea. Forget Novo Nordisk and buy another magnificent pharma stock instead.
Vertex Pharmaceuticals (NASDAQ: VRTX) doesn't share much in common with Novo Nordisk. For one thing, Vertex's market cap of $126 billion is only a fraction of Novo's market cap of over $450 billion.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
430,00 €
-0,36 %
Deutliches Buy-Überwiegen bei Vertex Pharmaceuticals Inc. im Vergleich zu Sell-Einschätzungen.
Dadurch ergibt sich bei einem Kursziel von 440 € ein leicht positives Potenzial von 2.33% im Vergleich zum aktuellen Kurs von 430.0 € bei Vertex Pharmaceuticals Inc..
